About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Anti-Rheumatics Market Size, Top Share, Demand, Forecast to 2031
Anti-Rheumatics Market

Anti-Rheumatics Market Size, Share & Trends Analysis Report By Drug Class (Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Others), By Type (Prescription-Based Drugs, Over-the-Counter Drugs) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI55734DR
Author : Debashree Bora
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Anti-Rheumatics Market Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Disease Modifying Anti-Rheumatic Drugs
        1. By Value
      3. Nonsteroidal Anti-inflammatory Drugs
        1. By Value
      4. Corticosteroids
        1. By Value
      5. Uric Acid Drugs
        1. By Value
      6. Others
        1. By Value
    3. By Type
      1. Introduction
        1. Type By Value
      2. Prescription-Based Drugs
        1. By Value
      3. Over-the-Counter Drugs
        1. By Value
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Disease Modifying Anti-Rheumatic Drugs
        1. By Value
      3. Nonsteroidal Anti-inflammatory Drugs
        1. By Value
      4. Corticosteroids
        1. By Value
      5. Uric Acid Drugs
        1. By Value
      6. Others
        1. By Value
    3. By Type
      1. Introduction
        1. Type By Value
      2. Prescription-Based Drugs
        1. By Value
      3. Over-the-Counter Drugs
        1. By Value
    4. U.S.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Disease Modifying Anti-Rheumatic Drugs
          1. By Value
        3. Nonsteroidal Anti-inflammatory Drugs
          1. By Value
        4. Corticosteroids
          1. By Value
        5. Uric Acid Drugs
          1. By Value
        6. Others
          1. By Value
      2. By Type
        1. Introduction
          1. Type By Value
        2. Prescription-Based Drugs
          1. By Value
        3. Over-the-Counter Drugs
          1. By Value
    5. Canada
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Disease Modifying Anti-Rheumatic Drugs
        1. By Value
      3. Nonsteroidal Anti-inflammatory Drugs
        1. By Value
      4. Corticosteroids
        1. By Value
      5. Uric Acid Drugs
        1. By Value
      6. Others
        1. By Value
    3. By Type
      1. Introduction
        1. Type By Value
      2. Prescription-Based Drugs
        1. By Value
      3. Over-the-Counter Drugs
        1. By Value
    4. U.K.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Disease Modifying Anti-Rheumatic Drugs
          1. By Value
        3. Nonsteroidal Anti-inflammatory Drugs
          1. By Value
        4. Corticosteroids
          1. By Value
        5. Uric Acid Drugs
          1. By Value
        6. Others
          1. By Value
      2. By Type
        1. Introduction
          1. Type By Value
        2. Prescription-Based Drugs
          1. By Value
        3. Over-the-Counter Drugs
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Disease Modifying Anti-Rheumatic Drugs
        1. By Value
      3. Nonsteroidal Anti-inflammatory Drugs
        1. By Value
      4. Corticosteroids
        1. By Value
      5. Uric Acid Drugs
        1. By Value
      6. Others
        1. By Value
    3. By Type
      1. Introduction
        1. Type By Value
      2. Prescription-Based Drugs
        1. By Value
      3. Over-the-Counter Drugs
        1. By Value
    4. China
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Disease Modifying Anti-Rheumatic Drugs
          1. By Value
        3. Nonsteroidal Anti-inflammatory Drugs
          1. By Value
        4. Corticosteroids
          1. By Value
        5. Uric Acid Drugs
          1. By Value
        6. Others
          1. By Value
      2. By Type
        1. Introduction
          1. Type By Value
        2. Prescription-Based Drugs
          1. By Value
        3. Over-the-Counter Drugs
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Singapore
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Disease Modifying Anti-Rheumatic Drugs
        1. By Value
      3. Nonsteroidal Anti-inflammatory Drugs
        1. By Value
      4. Corticosteroids
        1. By Value
      5. Uric Acid Drugs
        1. By Value
      6. Others
        1. By Value
    3. By Type
      1. Introduction
        1. Type By Value
      2. Prescription-Based Drugs
        1. By Value
      3. Over-the-Counter Drugs
        1. By Value
    4. UAE
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Disease Modifying Anti-Rheumatic Drugs
          1. By Value
        3. Nonsteroidal Anti-inflammatory Drugs
          1. By Value
        4. Corticosteroids
          1. By Value
        5. Uric Acid Drugs
          1. By Value
        6. Others
          1. By Value
      2. By Type
        1. Introduction
          1. Type By Value
        2. Prescription-Based Drugs
          1. By Value
        3. Over-the-Counter Drugs
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Disease Modifying Anti-Rheumatic Drugs
        1. By Value
      3. Nonsteroidal Anti-inflammatory Drugs
        1. By Value
      4. Corticosteroids
        1. By Value
      5. Uric Acid Drugs
        1. By Value
      6. Others
        1. By Value
    3. By Type
      1. Introduction
        1. Type By Value
      2. Prescription-Based Drugs
        1. By Value
      3. Over-the-Counter Drugs
        1. By Value
    4. Brazil
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Disease Modifying Anti-Rheumatic Drugs
          1. By Value
        3. Nonsteroidal Anti-inflammatory Drugs
          1. By Value
        4. Corticosteroids
          1. By Value
        5. Uric Acid Drugs
          1. By Value
        6. Others
          1. By Value
      2. By Type
        1. Introduction
          1. Type By Value
        2. Prescription-Based Drugs
          1. By Value
        3. Over-the-Counter Drugs
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Anti-Rheumatics Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. UCB S.A.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Pfizer Inc.
    3. AbbVie Inc.
    4. Eli Lilly and Company
    5. Johnson & Johnson
    6. Novartis AG
    7. Amgen Inc.
    8. F. HOFFMANN-LA ROCHE LTD.
    9. BRISTOL-MYERS SQUIBB COMPANY
    10. Merck & Co. Inc.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Bispecific Antibodies Market Size The global bispecific antibodies market size was valued at USD 11.84 billion in 2024 and is expected to grow from USD 17.10 billion in 2025 to USD 323.21 billion by 2033, growing at a CAGR of 44.4% du
Buy Now
Global Report
X-Ray Inspection System Market Size The global x-ray inspection system market size was valued at USD 834.65 million in 2024 and is expected to grow from USD 889.74 million in 2025 to reach USD 1483.61 million by 2033, growin
Buy Now
Global Report
Inflight Catering Market Size and Trends The global inflight catering market size was valued at USD 13.62 billion in 2023. It is projected to reach from USD 15.16 billion in 2024 to USD 35.75 billion by 2032, growing at a CAGR of 11.32% during the f
Buy Now
Global Report
Bladder Scanners Market Size The global bladder scanners market size was valued at USD 149.28 million in 2024 and is projected to grow from USD 162.36 million in 2025 to reach USD 270.46 million by 2033, exhibiting a CA
Buy Now
Global Report
Hair Removal Wax Market Size The global hair removal wax market size was valued at USD 14426.26 million in 2024 and is projected to reach from USD 15133.14 million in 2025 to USD 22188.76 million by 2033, growing at a CAGR of 4.9% during t
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright . All rights Reserved.